Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority Review Vouchers One Step Closer, But Congress Must Act Again

Executive Summary

FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies

You may also be interested in...



Voucher Does Not Guarantee A Priority Review, FDA Says

Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.

Patent Office Mulls Voucher For Fast-Track Re-exam If Firms Create "Humanitarian" Technology

The Patent and Trademark Office was inspired by FDA’s priority review voucher program to encourage companies to develop drugs for neglected tropical diseases. PTO is considering a similar strategy to reward patent owners who develop and license technologies with humanitarian uses.

Patent Office Mulls Voucher For Fast-Track Re-exam If Firms Create "Humanitarian" Technology

The Patent and Trademark Office was inspired by FDA’s priority review voucher program to encourage companies to develop drugs for neglected tropical diseases. PTO is considering a similar strategy to reward patent owners who develop and license technologies with humanitarian uses.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel